Codexis Delivers Strong Q2 Results - Can The Stock Rebound?

Shares of Codexis Inc. (CDXS) are currently trading at a significant discount compared to their 52-week high of $6.08, recorded in December of last year, with the stock now priced around $3.

Codexis is a biotechnology company specializing in enzymatic solutions designed to enable efficient and scalable production of complex therapeutics through its proprietary CodeEvolver technology platform. The company operates across two core segments - Pharma Biocatalysis and Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis manufacturing platform.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com